share_log

T2 Biosystems | 8-K: Voting Results of Special Shareholders' Meeting

T2 Biosystems | 8-K: Current report

T2 Biosystems | 8-K：重大事件
SEC announcement ·  04/12 16:53
Moomoo AI 已提取核心信息
On April 11, 2024, T2 Biosystems, Inc., a company incorporated in Delaware and listed on the Nasdaq Capital Market under the trading symbol TTOO, held a special meeting of stockholders. The meeting was conducted to vote on the approval of the CRG Debt to Equity Conversion. Stockholders representing approximately 35.86% of the voting power of the issued and outstanding common stock were present either in person via live webcast or by proxy. The proposal for the CRG Debt to Equity Conversion received overwhelming support with 1,684,394 votes for, 60,832 against, and 23,645 abstentions, leading to its approval. The definitive Proxy Statement provided additional information on the proposals submitted to stockholders.
On April 11, 2024, T2 Biosystems, Inc., a company incorporated in Delaware and listed on the Nasdaq Capital Market under the trading symbol TTOO, held a special meeting of stockholders. The meeting was conducted to vote on the approval of the CRG Debt to Equity Conversion. Stockholders representing approximately 35.86% of the voting power of the issued and outstanding common stock were present either in person via live webcast or by proxy. The proposal for the CRG Debt to Equity Conversion received overwhelming support with 1,684,394 votes for, 60,832 against, and 23,645 abstentions, leading to its approval. The definitive Proxy Statement provided additional information on the proposals submitted to stockholders.
2024年4月11日，在特拉华州注册并在纳斯达克资本市场上市，交易代码为TTOO的公司T2 Biosystems, Inc. 举行了一次特别股东会议。举行这次会议是为了对批准CRG债转股进行投票。占已发行和流通普通股投票权约35.86％的股东通过网络直播或通过代理人亲自出席。CRG债转股提案获得压倒性支持，获得1,684,394张赞成票，60,832票反对，23,645票弃权，最终获得批准。最终委托书提供了有关提交给股东的提案的更多信息。
2024年4月11日，在特拉华州注册并在纳斯达克资本市场上市，交易代码为TTOO的公司T2 Biosystems, Inc. 举行了一次特别股东会议。举行这次会议是为了对批准CRG债转股进行投票。占已发行和流通普通股投票权约35.86％的股东通过网络直播或通过代理人亲自出席。CRG债转股提案获得压倒性支持，获得1,684,394张赞成票，60,832票反对，23,645票弃权，最终获得批准。最终委托书提供了有关提交给股东的提案的更多信息。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息